Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
Public ClinicalTrials.gov record NCT00035425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
Study identification
- NCT ID
- NCT00035425
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2001 (Type not available)
- Primary completion
- Not listed
- Completion
- Nov 2002 (Actual)
- Last update posted
- Dec 1, 2009
2001 – 2002
United States locations
- U.S. sites
- 16
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62701-1014 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62703 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62769 | — |
| Pfizer Investigational Site | Springfield | Illinois | 62781 | — |
| Pfizer Investigational Site | The Bronx | New York | 10461 | — |
| Pfizer Investigational Site | The Bronx | New York | 10467 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23226 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23229 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23249 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23294-4367 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23294 | — |
| Pfizer Investigational Site | Federal Way | Washington | 98003 | — |
| Pfizer Investigational Site | Lakewood | Washington | 98499 | — |
| Pfizer Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00035425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2009 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00035425 live on ClinicalTrials.gov.